Mortality Risk High for Some Gleason Grade 1 Prostate Cancer Patients
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 1, 2024 -- For patients with Gleason Grade Group (GGG) 1 prostate cancer (PC), those with percentage positive biopsies (PPB) >50 percent or prostate-specific antigen (PSA) >20 ng/mL have a significantly increased risk for adverse outcomes, according to a study published online July 2 in European Urology Oncology.
Derya Tilki, M.D., from University Hospital Hamburg-Eppendorf in Germany, and colleagues examined the association of clinical factors at presentation with the presence of unsampled high-risk PC and PC-specific mortality (PCSM) and all-cause mortality following radical prostatectomy in a study population composed of 10,228 patients treated for GGG1 PC diagnosed via transrectal ultrasound-guided systematic biopsy (SBx) or combined biopsy (CBx).
The researchers found that PPB >50 percent and PSA >20 ng/mL were significantly associated with a higher risk for adverse pathology, regardless of biopsy approach (SBx: adjusted odds ratios [aORs], 1.71 and 3.49; CBx: aORs, 1.81 and 2.82, respectively) and with early PSA failure (SBx: adjusted hazard ratios [aHRs], 1.54 and 4.37; CBx: aHRs, 2.88 and 7.81, respectively). In the SBx group, PPB >50 percent and PSA >20 ng/mL were also associated with a higher risk for PCSM (aHRs, 2.56 and 3.71, respectively) and with all-cause mortality (aHRs, 1.47 and 2.00, respectively).
"For patients with GGG1 who are at heightened risk, we should continue to call their diagnosis cancer and we should report it back to their physician so that they can act on this information," senior author Anthony V. D'Amico, M.D., Ph.D., from Brigham and Women's Hospital in Boston, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality
FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...
Increased Liver Enzyme Levels Seen With Use of Cannabidiol in Adults
THURSDAY, July 10, 2025 -- Use of cannabidiol (CBD) within the range consumers are taking with unregulated CBD products is associated with increased liver enzyme levels, according...
Majority of Patients With Lyme Disease Do Not Follow Up With Clinician
THURSDAY, July 10, 2025 -- Only 34 percent of patients with erythema migrans >5 cm are positive for Lyme disease by a standard two-tier testing (STTT) algorithm, and of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.